Abstract 89P
Background
To understand adjuvant therapy use and clinical burden in patients (pts) with completely resected stage IB-IIIA NSCLC, this study described adjuvant therapy treatment pattern, OS, and DFS following surgery in the early-stage NSCLC population.
Methods
This retrospective study used data from the ConcertAI Patient360™ database, primarily drawn from United States (US) community oncology practices. Pts with a primary diagnosis of stage IB to IIIA NSCLC were eligible if they had undergone complete resection prior to March 1, 2016. Pts with neoadjuvant therapy or impaired performance were excluded. Adjuvant therapy use was summarized, and OS/DFS using Kaplan-Meier (KM) methods were examined by stage at initial diagnosis. Data cutoff was July 1, 2021.
Results
The study included 441 pts (median age 67 years, 50.3% male), of whom 153 pts had stage IB, 183 had stage II, and 105 had stage IIIA. The proportion of patients receiving adjuvant therapy after complete resection was highest in stage IIIA (50.5%), followed by stage II (42.1%) and stage IB (15.7%). The most common adjuvant regimen was platinum-based therapy with docetaxel or paclitaxel (41.6%). Median OS was 86.5 months for stage IB, 79.4 months for stage II, and 71.7 months for stage IIIA. KM-estimated survival rate at 5 years was 72.6% for stage IB, 64.0% for stage II, and 58.5% for stage IIIA. Median DFS was 57.8 months for stage IB, 36.6 months for stage II, and 34.4 months for stage IIIA. KM-estimated DFS rate at 3 years was 63.6% for stage IB, 51.8% for stage IIB, and 48.7% for stage IIIA.
Conclusions
Although recommended by clinical guidelines, the rate of adjuvant therapy delivery was low in pts with early-stage NSCLC following resection in US oncology practices. Worse outcomes were observed in pts with higher disease stage at diagnosis. Survival rates were higher for patients with stage II and IIIA NSCLC than historical benchmarks.
Legal entity responsible for the study
ConcertAI.
Funding
Merck & Co., Inc.
Disclosure
H. West: Financial Interests, Personal, Other, Consultant: Amgen; Financial Interests, Personal, Speaker’s Bureau: AstraZeneca; Financial Interests, Personal, Other, Consultant: AstraZeneca; Financial Interests, Personal, Other, Consultant: Eli Lilly; Financial Interests, Personal, Speaker’s Bureau: Genentech/Roche; Financial Interests, Personal, Other, Consultant: Genentech/Roche; Financial Interests, Personal, Advisory Board: Merck & Co., Inc; Financial Interests, Personal, Other, Consultant: Merck & Co., Inc; Financial Interests, Personal, Other, Consultant: Mirati; Financial Interests, Personal, Other, Consultant: Pfizer; Financial Interests, Personal, Other, Consultant: Regeneron. X. Hu: Financial Interests, Personal, Full or part-time Employment: MSD, Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA; Financial Interests, Personal, Stocks/Shares: Merck & Co., Inc., Kenilworth, NJ, USA. T. Burke: Financial Interests, Personal, Full or part-time Employment: MSD, Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA; Financial Interests, Personal, Stocks/Shares: Merck & Co., Inc., Kenilworth, NJ, USA. M.S. Walker: Financial Interests, Personal, Full or part-time Employment: ConcertAI; Financial Interests, Institutional, Funding: Merck & Co., Inc. Y. Wang: Financial Interests, Personal, Full or part-time Employment: ConcertAI; Financial Interests, Institutional, Funding: Merck & Co., Inc. A. Samkari: Financial Interests, Personal, Full or part-time Employment: MSD, Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA ; Financial Interests, Personal, Stocks/Shares: Merck & Co., Inc., Kenilworth, NJ, USA.